NCT01185158View on ClinicalTrials.gov

A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

May 31, 2002

Primary Completion Date

August 31, 2004

Study Completion Date

November 30, 2010

Conditions
Head and Neck Cancer
Interventions
DRUG

ZD1839 (IRESSA)

ZD1839: 250mg/day po or via g-tube Q 24 hours

Trial Locations (1)

60653

The University of Chicago Medical Center, Chicago

All Listed Sponsors
lead

University of Chicago

OTHER

NCT01185158 - A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter